Advertisement

Breast Cancer Research and Treatment

, Volume 30, Issue 2, pp 179–195 | Cite as

Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer

  • Michael A. Levesque
  • Eleftherios P. Diamandis
  • He Yu
  • Donald J. A. Sutherland
Report

Abstract

Breast tumors are thought to originate, grow, and metastasize in an environment which includes steroid hormone receptors, their cognate steroid ligands, and many gene products which are regulated by steroid hormone receptor-ligand complexes. In this paper we describe highly sensitive and quantitative immunofluorometric procedures for measuring three proteins that are candidate prognostic indicators in breast cancer, namely, the p53 tumor suppressor gene product, carcinoembryonic antigen (CEA), and prostate specific antigen (PSA). These proteins were quantified in over 950 cytosolic tumor extracts along with estrogen and progesterone receptors (ER, PR). Association analysis between all five biochemical parameters revealed strong negative associations between p53 and receptors and strong positive associations between CEA and receptors. Negative associations between p53 and CEA and between CEA and PSA were also found. These associations, not quantitatively studied in previous reports, are related to each other using a hypothetical model. The observed associations may further contribute to the understanding of the biology of breast tumors.

Key words

p53 tumor suppressor gene prognostic indicators in breast cancer prostate specific antigen in breast cancer carcinoembryonic antigen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harris JR, Lippman ME, Veronesi U, Willett W: Breast Cancer. New Engl J Med 1992; 327: 319–328Google Scholar
  2. 2.
    Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–187Google Scholar
  3. 3.
    Rosner D, Lane WW: Node negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy. Cancer 1990; 66: 199–205Google Scholar
  4. 4.
    McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. New Engl J Med 1992; 326: 1756–1761Google Scholar
  5. 5.
    McGuire WL, Tandon AK, Alfred DG, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 1006–1015Google Scholar
  6. 6.
    Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 1980; 40: 1890–1896Google Scholar
  7. 7.
    Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour G, Abeloff MD, McGuire WL: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992; 10: 428–432Google Scholar
  8. 8.
    Keyhani-Rofagha S, O'Toole RV, Farrar WB, Sickle-Santa-nello B, DeCenzo J, Young D: Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 1990; 65: 1577–1582Google Scholar
  9. 9.
    LeDoussal V, Tubiana-Hulin M, Hacene K, Friedman S, Brunet M: Nuclear characteristics as indicators of prognosis in node-negative breast cancer patients. Breast Cancer Res Treat 1989; 14: 207–216Google Scholar
  10. 10.
    Contesso G, Saccani Jotti G, Bonadonna G: Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 1989; 25: 403–409Google Scholar
  11. 11.
    Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 1076–1087Google Scholar
  12. 12.
    Chevallier B, Heintzman F, Mosseri V, Dauce JP, Bastit P, Graic Y, Brunelle P, Basuyau JP, Comoz M, Asselain B: Prognostic value of estrogen and progesterone receptor in operable breast cancer. Cancer 1988; 62: 2517–2524Google Scholar
  13. 13.
    McGuire WL: Estrogen receptor versus grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 1988; 6: 1071–1072Google Scholar
  14. 14.
    Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–6014Google Scholar
  15. 15.
    Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL, Horne CHW: Prognostic significance of the estrogen-related protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 1990; 65: 265–271Google Scholar
  16. 16.
    Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944–948Google Scholar
  17. 17.
    Gullick WJ, Love SB, Wright CA, Barnes DM, Gusterson B, Harris A, Altman B: C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–438Google Scholar
  18. 18.
    Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: Clinical, histologic and prognostic correlations. J Natl Cancer Inst 1991; 83: 170–178Google Scholar
  19. 19.
    Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, King CR, Porter-Jordan K, Wargotz ER, Liotta LA, Steeg PS: Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991; 139: 245Google Scholar
  20. 20.
    Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875–1887Google Scholar
  21. 21.
    Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403–408Google Scholar
  22. 22.
    Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SM, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–708Google Scholar
  23. 23.
    Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991; 351: 453–456Google Scholar
  24. 24.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991; 253: 49–53Google Scholar
  25. 25.
    Chen PL, Chen Y-M, Bookstein R, Lee W-M: Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–1580Google Scholar
  26. 26.
    Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–1093Google Scholar
  27. 27.
    Prosser J, Thompson AM, Cranston G, Evans HJ: Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene 1990; 5: 1573–1579Google Scholar
  28. 28.
    Gannon JV, Lane DP: p53 and DNA polymerase-α compete for binding to SV40 T antigen. Nature 1987; 329: 456–458Google Scholar
  29. 29.
    Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C: Wild-type p53 activates transcriptionin vitro. Nature 1992; 358: 83–85Google Scholar
  30. 30.
    Kuerbitz SJ, Punkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491–7495Google Scholar
  31. 31.
    Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849Google Scholar
  32. 32.
    Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms a hsc 70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531–539Google Scholar
  33. 33.
    Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, Shulsky G, Skurnik Y, Arai N, Rotter V, Oren M: Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 1988; 3: 313–321Google Scholar
  34. 34.
    Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1990; 88: 5006–5010Google Scholar
  35. 35.
    Mackay J, Steel CM, Elder DA, Forrest APM, Evans HJ: Allele loss on short arm of chromosome 17 in breast cancers. Lancet 1988; 11: 1389–1385Google Scholar
  36. 36.
    Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung B-M, Goodson W, Goldman ES, Moore D, Balazs M, Liu E, Mayall BH, Smith LS: Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 1991; 88: 3847–3851Google Scholar
  37. 38.
    Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumor suppressor in breast tissues and tumorsin situ andin vitro. Int J Cancer 1990; 46: 839–844Google Scholar
  38. 38.
    Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty V, Carter DC, Evans HJ, Steel CM: p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992; 50: 528–532Google Scholar
  39. 39.
    Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJW, Angus B, Horne CHW: p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 1991; 164: 75–81Google Scholar
  40. 40.
    Silvestrini R, Veneroni S, Benini E, Di Fronzo G, Daidone MG: p53 and cathepsin D are independent of established prognostic factors in breast cancers. Int J Oncol 1992; 1: 507–512Google Scholar
  41. 41.
    Davidoff AM, Herndon JE, Glover NS, Kerns B-JM, Pence JC, Iglehart D, Marks JR: Relationship between p53 over-expression and established prognostic factors in breast cancer. Surgery 1991; 110: 259–264Google Scholar
  42. 42.
    Sawan A, Randall B, Angus B, Wright C, Henry JA, Ostrowski J, Hennessy C, Lennard JW, Corbett I, Horne CHW: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. J Pathol 1992; 168: 23–28Google Scholar
  43. 43.
    Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Gariepy G: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1992; 23: 1388–1394Google Scholar
  44. 44.
    Clark JS, George WD, Campbell AM: Dual colour flow cytometry of p53 and c-erbB-2 expression related to DNA aneuploidy in primary and metastatic breast cancer. Cancer Letts 1992; 66: 193–200Google Scholar
  45. 45.
    Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G: Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat 1992; 421: 291–295Google Scholar
  46. 46.
    Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BM, Smith HS: Accumulation of the p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845–855Google Scholar
  47. 47.
    Allred DR, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–206Google Scholar
  48. 48.
    Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 1992; 84: 826–827Google Scholar
  49. 49.
    Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G: Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 1992; 66: 758–764Google Scholar
  50. 50.
    Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699–1703Google Scholar
  51. 51.
    Hassapoglidou S, Diamandis EP, Sutherland DJA: Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved fluorometry. Oncogene 1993; 8: 1501–1509Google Scholar
  52. 52.
    Schwartz MR, Randolph RL, Panko WB: Carcinoembryonic antigen and steroid receptors in the cytosol of carcinoma of the breast. Cancer 1985; 55: 2464–2471Google Scholar
  53. 53.
    Duffy MJ, O'Connell M, O'Sullivan, McKenna B, Allen MA, McDonnell L: CEA-like material in cytosols from human breast carcinomas. Cancer 1983; 51: 121–123Google Scholar
  54. 54.
    Keenan EJ, Hart NE: Specimen handling guidelines for steroid receptor analysis in breast cancer. Lab Med 1981; 12: 275–278Google Scholar
  55. 55.
    Lowry OH, Roseborough NJ, Farr AL, Randall RJ: Protein measurement with folin-phenol reagent. J Biol Chem 1951: 193: 265–275Google Scholar
  56. 56.
    Greene GL, Nolan C, Engler JP, Jensen EV: Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci USA 1980; 77: 5115–5119Google Scholar
  57. 57.
    Weigard RA, Cotter DL, Dunn RA, Nolan C, Greene G, Przywara LW: Quantification of progesterone receptor (PgR) in human breast tumors by double monoclonal enzyme immunoassay. Breast Cancer Res and Treat 1986; 8: 87Google Scholar
  58. 58.
    Thorpe SM: Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: Greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res 1987; 47: 6572–6575Google Scholar
  59. 59.
    Christopoulos TK, Diamandis EP: Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992; 64: 342–346Google Scholar
  60. 60.
    Hassapoglidou S, Diamandis EP: The p53 suppressor gene product quantified in cell lines, tumor tissue and biological fluids using an ultrasensitive time-resolved fluorescence immunoassay. Clin Biochem 1992; 25: 135Google Scholar
  61. 61.
    Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595–1602Google Scholar
  62. 62.
    Midgley CA, Fisher C, Bartek J, Vojtesek B, Lane DP, Barnes DM: Analysis of p53 expression in human tumors: An antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101: 183–189Google Scholar
  63. 63.
    Bhayana V, Diamandis EP: A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. Clin Biochem 1989; 22: 433–438Google Scholar
  64. 64.
    Yu H, Diamandis EP: Ultrasensitive time-resolved immunofluorometric assay of prostate specific antigen in serum and preliminary clinical studies. Clin Chem 1993; 39: 2108–2114Google Scholar
  65. 65.
    Diamandis EP, Yu H, Sutherland DJA: Production of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat (in press)Google Scholar
  66. 66.
    Yu H, Diamandis EP, Grass L: Prostate specific antigen gene derepression by steroids and tamoxifen in the breast cancer cell line T-47D. Submitted, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Michael A. Levesque
    • 1
    • 2
  • Eleftherios P. Diamandis
    • 1
    • 2
  • He Yu
    • 1
    • 2
  • Donald J. A. Sutherland
    • 3
  1. 1.Department of Clinical BiochemistryToronto Western Division, The Toronto HospitalToronto, OntarioCanada
  2. 2.Department of Clinical BiochemistryUniversity of TorontoToronto, OntarioCanada
  3. 3.Toronto Bayview Regional Cancer Centre, Sunnybrook Health Science CentreUniversity of TorontoToronto, OntarioCanada

Personalised recommendations